Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features
- PMID: 10825360
- DOI: 10.1093/brain/123.6.1229
Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features
Abstract
The cluster in Jews of Libyan origin of limb-girdle muscular dystrophy type 2B due to a dysferlin 1624delG mutation is described. The carrier frequency of this mutation is calculated to be approximately 10% in this population, in which the disease prevalence is at least 1 per 1300 adults. Twenty-nine patients from 12 families were all homozygous for the same mutation. However, clinical features were heterogeneous even within the same family: in half of the patients onset was in the distal muscles of the legs, which is similar to Miyoshi myopathy, while in others onset was in the proximal musculature, which is similar to other forms of limb-girdle dystrophies. Age at onset varied from 12 to 28 years (mean 20.3 +/- 5.5 years). One patient was presymptomatic at age 28 years. Progression was slow regardless of age of onset, patients remaining ambulatory until at least 33 years. Five patients described subacute, painful enlarged calves as an early, unusual feature. The variable features in this ethnic cluster contribute to the definition of the clinical spectrum of dysferlinopathies in general. The cause of the observed heterogeneity remains unclear.
Similar articles
-
A new dysferlin gene mutation in two Japanese families with limb-girdle muscular dystrophy 2B and Miyoshi myopathy.Neuromuscul Disord. 2001 Mar;11(2):139-45. doi: 10.1016/s0960-8966(00)00168-1. Neuromuscul Disord. 2001. PMID: 11257469
-
Identical dysferlin mutation in limb-girdle muscular dystrophy type 2B and distal myopathy.Neurology. 2000 Dec 26;55(12):1931-3. doi: 10.1212/wnl.55.12.1931. Neurology. 2000. PMID: 11134403
-
Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s).Hum Mol Genet. 1999 May;8(5):871-7. doi: 10.1093/hmg/8.5.871. Hum Mol Genet. 1999. PMID: 10196377
-
Dysferlin and the plasma membrane repair in muscular dystrophy.Trends Cell Biol. 2004 Apr;14(4):206-13. doi: 10.1016/j.tcb.2004.03.001. Trends Cell Biol. 2004. PMID: 15066638 Review.
-
Translational research and therapeutic perspectives in dysferlinopathies.Mol Med. 2011 Sep-Oct;17(9-10):875-82. doi: 10.2119/molmed.2011.00084. Epub 2011 May 6. Mol Med. 2011. PMID: 21556485 Free PMC article. Review.
Cited by
-
The Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism and Genetic Approaches for Treatments.Biomolecules. 2024 Feb 21;14(3):256. doi: 10.3390/biom14030256. Biomolecules. 2024. PMID: 38540676 Free PMC article. Review.
-
Gene-editing in patient and humanized-mice primary muscle stem cells rescues dysferlin expression in dysferlin-deficient muscular dystrophy.Nat Commun. 2025 Jan 2;16(1):120. doi: 10.1038/s41467-024-55086-0. Nat Commun. 2025. PMID: 39747848 Free PMC article.
-
Functional recovery of a novel knockin mouse model of dysferlinopathy by readthrough of nonsense mutation.Mol Ther Methods Clin Dev. 2021 May 1;21:702-709. doi: 10.1016/j.omtm.2021.04.015. eCollection 2021 Jun 11. Mol Ther Methods Clin Dev. 2021. PMID: 34141825 Free PMC article.
-
Analysis of Exon Skipping Applicability for Dysferlinopathies.Cells. 2025 Jan 24;14(3):177. doi: 10.3390/cells14030177. Cells. 2025. PMID: 39936969 Free PMC article. Review.
-
Genetic screening of an endemic mutation in the DYSF gene in an isolated, mountainous population in the Republic of Dagestan.Mol Genet Genomic Med. 2023 Oct;11(10):e2236. doi: 10.1002/mgg3.2236. Epub 2023 Aug 8. Mol Genet Genomic Med. 2023. PMID: 37553796 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical